TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04519879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White Button Mushroom Extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White Button Mushroom Extract
Description: Given PO
Study: NCT06060522

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT, CBCT
Description: Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT, CBCT
Description: Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline.
Study: NCT05327322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycemic load
Description: Participants will be provided food to meet GL prescription for the duration of the trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic load
Description: Participants will be provided food to meet GL prescription for the duration of the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restriction
Description: Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral support
Description: All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
Study: NCT05449080

Intervention type: DIAGNOSTIC_TEST
Intervention: Karyotype
Description: Patients were subjected to karyotype to determine their genotype
Study: NCT06454214

Intervention type: DEVICE
Intervention: Multi-photon microscopy
Description: To conduct 3D structural imaging on human breast tissues

Intervention type: DEVICE
Intervention: Multi-photon microscopy
Description: To conduct 3D structural imaging on human breast tissues
Study: NCT05219435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
Study: NCT05938283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator implant
Description: ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator implant
Description: ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
Study: NCT05772130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive family letter and genomic test report

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Contact
Description: Receive family letter and genomic test report with provider-mediated contact

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06379620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)
Description: Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
Study: NCT05770180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant vaccine (Sf9 cell)
Description: WSK-V102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant vaccine (Sf9 cell)
Description: WSK-V102

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (CHO cell)
Description: control 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: control 2
Study: NCT06441188

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thin layer conventional ultrasound coupling gel
Description: The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thick layer of conventional ultrasound coupling gel
Description: The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thin conventional ultrasound coupling gel pad
Description: The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thick conventional ultrasound coupling gel pad
Description: The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
Study: NCT05596812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Care Pathway
Description: The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
Study: NCT05005754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
Study: NCT05157672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon (2 g)
Description: oral capsules, 2 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon (2 g)
Description: oral capsules, 2 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2.5 mg)
Description: gum, 2.5 mg
Study: NCT05936281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for injection
Description: 150 mg/1ml/ vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg/table
Study: NCT04965051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart (IDegAsp)
Description: To evaluate the efficacy and safety of the IDegAsp in T1DM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin plus pre-prandial insulin
Description: To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
Study: NCT06556173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX3232
Description: Dose A
Study: NCT06640543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
Study: NCT04558281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active ropivacaine 0.3% erector spinae plane perineural administration
Description: Ropivacaine 0.3% administration via an erector spinae plane perineural catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo erector spinae plane perineural administration
Description: Normal saline administration via an erector spinae plane perineural catheter
Study: NCT05613803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: 6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
Study: NCT06195683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
Study: NCT05492110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary sinus reducer
Description: The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure
Description: Implantation procedure with no device implanted

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary physiology
Description: Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Invasive coronary physiology
Description: Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
Study: NCT06218212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastart formula
Description: * Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
Description: calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Study: NCT04594148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-shift training
Description: Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
Study: NCT05157672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2.5 mg)
Description: gum, 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Description: tablet, 2.5 mg
Study: NCT06474806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-AE105
Description: AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-AE105
Description: AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-AE105
Description: AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
Study: NCT06118619

Intervention type: DRUG
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT05157672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Description: tablet, 2.5 mg
Study: NCT06514469

Intervention type: DRUG
Intervention: Sufentanil intravenous administration followed consultation of remote physician
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.

Intervention type: DRUG
Intervention: Sufentanil intravenous administration based on paramedic competency
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
Study: NCT05041192

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell
Description: 7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
Study: NCT05544370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive high intensity intervallic training group
Description: The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive high-intensity intervallic training
Description: The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
Study: NCT06063772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers, Intravenous
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
Study: NCT05078827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (A): Fluorouracil Cream, 5% topical cream
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study: NCT06640920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Administered IV High dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Administered SC Low Dose
Study: NCT04804839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First research arm
Description: Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second research arm
Description: Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Third research arm
Description: It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
Study: NCT06640920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort C
Description: Administered SC Mid Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort D
Description: Administered SC High Dose
Study: NCT06641622

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of delayed graft function
Description: Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
Study: NCT06638125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping
Description: All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping
Description: The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.